PARP-1抑制剂与其他药物联用克服卵巢癌耐药性的研究进展  

Research Progress of PARP-1 Inhibitors Combined with Other Drugs to Overcome Drug Resistance in Ovarian Cancer

作　　者：陈佃成 杨英捷 李丹青 CHEN Diancheng;YANG Yingjie;LI Danqing(Guizhou Medical University,Guiyang 550000,China;Department of Gynecological Tumor Surgery,the Affiliated Cancer Hospital of Guizhou Medical University,Guiyang 550000,China)

机构地区：[1]贵州医科大学,贵阳550000 [2]贵州医科大学附属肿瘤医院妇瘤外科,贵阳550000

出　　处：《医学综述》2023年第6期1150-1155,共6页Medical Recapitulate

基　　金：贵州省卫生健康委科学技术基金项目(gzwkj2021-307)。

摘　　要：近年随着聚腺苷二磷酸核糖聚合酶-1(PARP-1)抑制剂的临床应用,某些肿瘤患者的结局得到显著改善,尤其是高级别浆液性卵巢癌。虽然PARP-1抑制剂可提高卵巢癌患者的无进展生存期,但长期应用会产生耐药性。PARP-1抑制剂与其他药物联合治疗或可克服耐药性问题,两者可通过协同作用或替代策略靶向同源重组修复,从而恢复同源重组缺陷。目前关于PARP-1抑制剂与其他抗肿瘤疗法联合应用的研究正在积极进行中,未来深入了解PARP-1抑制剂的耐药机制以及用药组合可以为解决临床卵巢癌耐药问题提供新方向。In recent years,with the clinical application of polyadenosine diphosphate ribose polymerase-1(PARP-1)inhibitors,the outcomes of some tumor patients,especially high-grade serous ovarian cancer,have been significantly improved.Although PARP-1 inhibitors can improve the progression-free survival of ovarian cancer patients,long-term application will lead to drug resistance.The combination of PARP-1 inhibitors with other drugs may overcome the problem of drug resistance,which can recover the defects of homologous recombination by targeting homologous recombination repair by synergy effect or by alternative strategies.At present,research on the combination of PARP-1 inhibitors and other anti-tumor therapies is actively underway.In the future,understanding the drug resistance mechanism and drug combination of PARP-1 inhibitors will provide a new direction for solving the drug resistance problem of ovarian cancer in clinical.

关 键 词：卵巢癌 耐药性 聚腺苷二磷酸核糖聚合酶-1 聚腺苷二磷酸核糖聚合酶-1抑制剂 

分 类 号：R711[医药卫生—妇产科学]